Analytical Data
-
Gene name
ACAN
- Application
-
Alternative Names
ACAN; AGC1; CSPG1; MSK16
-
Species
Human
-
Source
HEK293
-
Tag
C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6PID9
-
Expression Region
A17-L721
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
90-130 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ACAN, or aggrecan, is a significant extracellular matrix (ECM) protein primarily found in cartilage, playing a critical role in providing resistance to compression and maintaining tissue hydration. Research into ACAN has garnered attention due to its association with various musculoskeletal disorders, including osteoarthritis and intervertebral disc degeneration. Given the increasing incidence of these conditions in aging populations, understanding the structure and function of ACAN, as well as its role in cartilage homeostasis, is essential. Investigating the recombinant expression of ACAN has allowed scientists to explore its therapeutic potential and implications for tissue engineering. By employing biotechnological methods to produce functional ACAN molecules, researchers aim to elucidate the protein's biochemical properties and interactions within the ECM. This research not only enhances our knowledge of cartilage biology but also paves the way for novel regenerative therapies that could improve the quality of life for individuals suffering from cartilage-related diseases. The ongoing exploration of ACAN's role and the potential of its recombinant forms signifies a crucial step toward developing effective treatments for joint disorders and advancing the field of regenerative medicine.
